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Abstract
The presentation of several autoimmune neurological disorders in a single patient is rare and often
debilitating. However, early diagnosis and efficacious treatment can lead to a significant recovery. Here, we
present an interesting case of a triple antibody-positive autoimmune neurological syndrome patient who
manifested the clinical features of neuromyelitis optica (NMO) spectrum disorder (NMOSD), N-methyl-Daspartate (NMDA) receptor (NMDAR) encephalitis, and myasthenia gravis (MG). Hence, the patient
manifested both central and peripheral nervous system immune-mediated neurological syndromes. A
middle-aged female with a history of seropositive aquaporin-4 (AQP4) NMOSD on mycophenolate 1 g twice
daily presented with severe fatigue and right eye ptosis (three months since NMOSD diagnosis) and tested
positive for acetylcholine receptor (AchR) binding antibody, consistent with MG. Six months after the
patient’s NMOSD diagnosis, she began to experience subacute progressive cognitive decline, behavioral
changes, imbalance, anxiety/panic attacks, and paranoid delusions. NMDAR encephalitis was suspected, and
she tested positive for cerebrospinal fluid NMDAR antibodies. After treatment with steroids failed, she was
given two doses of rituximab 1 g, two weeks apart, and reported improvement in her symptoms shortly after
the second dose.

Categories: Neurology, Allergy/Immunology, Rheumatology
Keywords: anti-nmda receptor encephalitis, autoimmune encephalitis, anti-achr antibody, aquaporin-4 (aqp4)
antibody, neuro-immunology, neuromyelitis optica spectrum disorder (nmosd), myasthenia gravis (mg)

Introduction
The co-existence of several autoimmune conditions has been reported with neuromyelitis optica (NMO)
spectrum disorders (NMOSD) [1]. While a rare disorder, there have been documented cases of concurrent Nmethyl-D-aspartate (NMDA) encephalitis and anti-aquaporin-4 (AQP4) NMOSD [2,3]. In a case series of 691
patients with anti-NMDA receptor (NMDAR) encephalitis, 23 patients were identified with overlapping
demyelinating syndromes associated with AQP4 and myelin oligodendrocyte glycoprotein (MOG) with
clinical and radiographic features preceded or followed by the demyelinating disease process [3]. Another
prospective observational study with the co-existence of MOG and AQP4 antibodies with anti-NMDAR
showed that 0.6% of patients with NMOSD had overlapping NMDAR encephalitis and 11.9% of patients had
anti-MOG disease [2]. The co-existence of myasthenia gravis (MG) has been reported with NMOSD [1].
In this case report, we present a middle-aged patient displaying the clinical manifestations of these three
rare neurological disorders (NMOSD, MG, and anti-NMDAR encephalitis). By presenting this unusual case,
we hope to help clinicians be more vigilant about the possibility of overlapping neurological syndromes that
will help avoid delays in the diagnosis and treatment of these conditions. This article was previously
presented as a meeting abstract at the 2022 American Academy of Neurology (AAN) Annual Meeting on
April 3, 2022.

Case Presentation
A 44-year-old previously healthy female presented to an outside hospital emergency department with a
headache followed by imbalance, right upper and lower extremity numbness, and weakness. Her
examination findings on admission were notable for 3/5 strength of her right upper and lower extremities.
She also had a loss of sensation in her right upper extremity. The rest of her examination was unremarkable.
She had a head computed tomography (CT) performed, which was unremarkable. Magnetic resonance
imaging (MRI) of the brain showed T2 hyperintensities in the bilateral hypothalamic regions and
pontomedullary junction, prominent on the left side without associated diffusion restriction and
enhancement (Figure 1A-1C). The patient refused a lumbar puncture and was told to follow up with a
neurology outpatient. At her three-month follow-up, she reported that her symptoms have gradually
improved with physical therapy and now only has residual right-handed numbness. As a demyelinating
process was suspected, she had an extensive neurological workup over the next three months. She
underwent a lumbar puncture with an opening pressure of 12 cm H2O, a protein count of 35 mg/dl, and a
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cell count of 1/mm3. Serum studies showed negative cell-based assay serology for AQP4 immunoglobulin (Ig)
G and MOG-IgG and mildly elevated ribonuclear protein (RNP) and Sjogren’s antibody for soluble substance
A/Ro (SS-Ro) (Table 1). Workup for sarcoidosis was negative with normal angiotensin-converting enzyme
levels and normal chest CT without mediastinal and hilar lymphadenopathy. MRI of the cervical spine
revealed T2 signal changes from the cervicomedullary junction to C3 level with faint enhancement
(Figure 1D, 1E). MRI of the thoracic spine was normal without signal changes. Cerebrospinal fluid analysis
and paraneoplastic panel were negative except for mildly elevated N-type calcium channel antibodies of 0.04
and mildly elevated IgG index of 0.8 (Table 2).

FIGURE 1: Magnetic resonance imaging (MRI) of the brain and cervical
spine
MRI of the brain fluid-attenuated inversion recovery axially showing T2 hyperintensities in the bilateral
hypothalamic regions (A, B) and pontomedullary junction (C), with interval resolution imaging after a year (F-H).
MRI of the cervical spine showing T2 signal changes from cervicomedullary junction to C3 level (D) with faint
gadolinium enhancement (E). Repeat MRI of the brain, interval of two years, showing new T2 hyperintensities in
the bilateral thalami (I, J). Repeat MRI of the cervical spine, interval of 18 months, showing improved T2
hyperintensities within cervical medullary junction (K), without enhancement (L)
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Laboratories

Values

Reference range and units

ANA screen and titer

Negative

Negative, <1:80 titer

Borrelia burgdorferi total IgG/IgM Ab

0.23

<0.90 index value

C-reactive protein

0.1

<0.5 mg/dl

Erythrocyte sedimentation rate

19

<20 mm/hour

HBsAg

Negative

Negative

HBc Ab IgM

Negative

Negative

Hepatitis C Ab

Negative

Negative

Hepatitis A Ab IgM

Negative

Negative

International normalized ratio

0.94

1

Myelin oligodendrocyte glycoprotein-IgG1

Negative

Negative

Neuromyelitis optica/aquaporin-4 IgG

Negative

Negative

N-Methyl-D-aspartate receptor Ab, IgG

<1:10

<1:10

Acetylcholine receptor Ab

0.53

<0.3 nmo/L

B2 glycoprotein IgG Ab

<9

<20 SGU

B2 glycoprotein IgM Ab

<9

<20 SMU

B2 glycoprotein IgA Ab

<9

<20 SMU

Angiotensin-converting enzyme

39

8-52 U/L

Methylmalonic acid

0.13

<0.40 umol/L

Quantiferon TB Plus

Negative

Negative

IgG

1939

700-1600 mg/dl

Albumin

3963

3848-5304 mg/dl

Ribonuclear protein Ab

1.8

<1.0 ELISA units

SM Ab

0.2

<1.0 ELISA units

SS A/Ro Ab

3.0

<1.0 ELISA units

SS B/La Ab

<0.2

<1.0 ELISA units

Treponemal IgG/IgM

Nonreactive

Nonreactive

C-ANCA

<1:20

<1:20 titer

P-ANCA

<1:20

<1:20 titer

PT

12.7

12.1-14.5 seconds

PTT

34

22-36 seconds

DRVVT

31

27-45 seconds

Lupus anticoagulant

37.5 seconds

30.3-43.2 seconds

DNA Ab (ds) Crithidia, IFA

Negative

Negative

TPMT enzyme activity

26.2

>21 EU

Cardiolipin Ab IgA

42.9

<12 APL

Cardiolipin Ab IgG

<9.0

<15 GPL

Cardiolipin Ab IgM

<9.0

<12.5 MPL

Vitamin B1, whole blood

50

38-122 ug/L

Varicella IgG Ab

2.6

<1.0 units
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Varicella IgM Ab

1.26

<0.9 index

Striated muscle Ab IgG

1:40

<1:40

AchR ganglionic neuronal Ab, S

0.00

<0.02 nmol/L

Amphiphysin Ab, S

Negative

<1:240 titer

AGNA-1, S

Negative

<1:240 titer

ANNA-1, S

Negative

<1:240 titer

ANNA-2, S

Negative

<1:240 titer

ANNA-3, S

Negative

<1:240 titer

CRMP-5-IgG, S

Negative

<1:240 titer

GAD65 Ab, S

0.00

0.02

Neuronal (V-G) K+ channel Ab, S

Negative

<0.02 nmol/L

N-type calcium channel Ab

0.04

<0.03 nmol/L

P/Q-type calcium channel Ab

0.00

<0.02 nmol/L

PCA-1, S

Negative

<1:240

PCA-2, S

Negative

<1:240

PCA-Tr, S

Negative

<1:240

Striational (striated muscle) Ab, S

Negative

<1:120

TABLE 1: Patient initial serum laboratory results with reference values
Ab: antibody; AchR: acetylcholine receptor; AGNA-1: anti-glial nuclear antibody type 1; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic
antibodies; ANNA: antineuronal nuclear antibody; C-ANCA: antineutrophil cytoplasmic autoantibody, cytoplasmic; CRMP-5: collapsin response-mediator
protein-5; ds: double-stranded; DRVVT: dilute Russell viper venom time; GAD: glutamic acid decarboxylase; HB: hepatitis B; Ig: immunoglobulin; P-ANCA:
perinuclear anti-neutrophil cytoplasmic antibodies; PCA: Purkinje cytoplasmic antibody; PCA-Tr: Purkinje cytoplasmic antibody titer; PT: prothrombin time;
PTT: partial thromboplastin time; S: serum; SM: smooth muscle; SS: Sjogren’s syndrome; TPMT: thiopurine S-methyltransferase; ELISA: enzyme-linked
immunosorbent assay; HBsAg: hepatitis B surface antigen; HBc: hepatitis B core; IFA: immunofluorescent assay

Initial
values

Repeat (18
months) values

Reference range and units

-

1:5

<1:1

West Nile IgG Abs

-

<1.3

<1.30 antibody not detected, 1.30-1.49 equivocal, and
>1.49 antibody detected

West Nile IgM Abs

-

<0.9

Varicella zoster, PCR

-

Not detected

Not detected

Cytomegalovirus PCR, qualitative

Not
detected

Not detected

Not detected

EBV DNA, PCR CSF

-

Not detected

Not detected

HSV 1 DNA

-

Not detected

HSV 2 DNA

-

Not detected

VDRL

Nonreactive

Nonreactive

Protein

34.9

50

15-55 mg/dl

Lactic acid

-

1.4

1.2-2.4 mmol/L

Laboratories
N-Methyl-D-aspartate receptor Ab IgG serum
with reflex to titer
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Glucose

64

58

40-80 mg/dl

Red blood cells

1

<3

0/mm3

White blood cells

1

7

0-5/mm 3

Neutrophils

0

0

0%-6%

Lymphocytes

94

97

40%-80%

Monocytes

6

2

15%-45%

Mononucleates

0

0

15%-45%

Macrophages

0

0

0%

Eosinophils

0

0

0%

Basophils

0

0

0%

IgG

7.4

6.1

0.5-6.1 mg/dl

Albumin

18.7

18.7

10-31 mg/dl

IgG index/CSF

0.8

0.8

0.3-0.7 ratio

Angiotensin-converting enzyme

<5

-

<15 U/L

Amphiphysin Ab, S

Negative

-

<1:240 titer

AGNA-1, S

Negative

-

<1:240 titer

ANNA-1, S

Negative

-

<1:240 titer

ANNA-2, S

Negative

-

<1:240 titer

ANNA-3, S

Negative

-

<1:240 titer

CRMP-5-IgG, S

Negative

-

<1:240 titer

PCA-1, S

Negative

-

<1:240

PCA-2, S

Negative

-

<1:240

PCA-Tr, S

Negative

-

<1:240

TABLE 2: Patient CSF initial and repeat (18 months later) laboratory results with reference values
Ab: antibody; AGNA-1: anti-glial nuclear antibody type 1; ANNA: antineuronal nuclear antibody; CSF: cerebrospinal fluid; CRMP-5: collapsin responsemediator protein-5; EBV: Epstein-Barr virus; HSV: herpes simplex virus; Ig: immunoglobulin; PCA: Purkinje cytoplasmic antibody; PCA-Tr: Purkinje
cytoplasmic antibody titer; PCR: polymerase chain reaction; S: serum; VDRL: venereal disease research laboratory

The patient was recommended clinical observation and a repeat MRI of the brain and NMO IgG in six
months. She had a repeat MRI of the brain a year later (delayed due to the COVID-19 pandemic), which
showed complete resolution of the initially reported T2 signal changes in the bilateral hypothalamus and
pontomedullary junction (Figure 1F-1H). Re-imaging of the cervical and thoracic spine was not performed at
this time. NMO IgG serology was repeated and was positive with a titer of 1:100 one year after she initially
tested negative (Table 1). To prevent future attacks, the patient was started on mycophenolate mofetil 1 g
twice daily for AQP4-positive NMOSD. A few months later, the patient presented with severe fatigue,
diplopia, anorexia, generalized weakness, and an unintentional 30 lb weight loss. Neurological examination
was normal except for mild right fatigable ptosis. Laboratory testing showed normal complete blood count;
comprehensive metabolic panel, thyroid profile, folate level, iron profile, and monoclonal protein
evaluation; and low normal vitamin B12 level of 189 pg/ml with normal methylmalonic acid. She had normal
glycated hemoglobin, parathyroid hormone, and vitamin D levels. Repeat antinuclear antigen was positive
with a titer of 1:320 homogenous. Due to her constellation of symptoms, she was tested for acetylcholine
receptor (AchR) binding antibodies, which were positive at 0.53 nmol/L, consistent with the diagnosis of MG.
The patient declined neurophysiological testing at that time. She underwent a chest/abdomen/pelvis CT for
evaluation of a thymoma, which was negative for malignancy. She was started on pyridostigmine 30 mg
three times/day for MG-related fatigue and generalized weakness.
Eighteen months after her NMOSD diagnosis, the patient presented with subacute progressive cognitive
decline, imbalance, and behavioral problems. She was accompanied by her sister, who reported that the
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patient was having severe panic attacks, bizarre behavior, paranoid delusions, and short-term memory
problems. Neither the patient nor her sister reported a history of anxiety. Neurological examination showed
mild cognitive impairment and impaired tandem gait. On the Montreal Cognitive Assessment, she scored
24/30 and showed difficulty with executive, visuospatial functioning, recall, and fluency. Given the subacute
progressive cognitive decline, there was a high suspicion of encephalitis and vasculitis. A repeat MRI of the
brain/cervical/thoracic spine was performed and showed new areas of T2 hyperintense foci within the
bilateral posterior thalami without associated enhancement (Figure 1I, 1J). In the cervical spine, there was
improvement in the previously reported T2 signal changes without new lesions (Figure 1K, 1L). The thoracic
spine showed only mild degenerative changes and was negative for any demyelinating lesions.
Repeat lumbar puncture showed normal cell count, glucose, and protein (Table 2). Cerebrospinal fluid viral
polymerase chain reactions were negative. Cerebrospinal fluid was positive for anti-NMDAR IgG at 1:5,
indicative of NMDAR encephalitis. Serum anti-NMDAR IgG was negative (Table 1). She was given a three-day
course of intravenous methylprednisolone 1 g without improvement. She had chest/abdomen/pelvis CT,
which showed a right ovarian cyst but was negative for malignancy. Transvaginal ultrasound was performed
and negative for a possible teratoma. The patient received rituximab 1 g, two doses, two weeks apart, and her
anxiety, behavioral symptoms, and cognition significantly improved.
The patient was seen most recently eight months after her first rituximab infusion. She has received two
rounds of infusions so far per her maintenance therapy plan. Her cognition and focal neurological deficits
have remained stable. She has not had a relapse of her NMOSD or MG symptoms. She continues to suffer
from anxiety and depression, which is being treated with clonazepam 0.5 mg at bedtime. Additionally, she
reported a new sugar craving and weight gain, which is thought to possibly be related to limbic involvement
of her NMDAR encephalitis. She was referred to behavior health for assistance in treating the symptoms, and
the patient will follow up before each infusion (every six months).

Discussion
While these three conditions are rare, there have been documented cases of concurrent NMOSD-NMDAR
encephalitis and NMOSD-MG [3-8]. We could not find any literature related to a patient who exhibited the
symptoms of these disorders while testing positive for all three antibodies (AQP4, AchR, and NMDAR) on
different occasions.
The clinical significance of patients with overlapping NMOSD-NMDA encephalitis remains unclear.
However, overlapping cases typically presented with more severe symptoms and required high-efficacy
treatment [3]. In prior documented cases, there does not appear to be a pattern of one condition preceding
the other. Patients who develop these disorders may test positive for only one antibody at the time of
diagnosis and later develop detectable levels of the other antibodies [2,3]. It is thought that the immune
upregulation involved in the pathogenesis of these syndromes may increase one’s susceptibility to other
autoimmune disorders. These two conditions have very different clinical manifestations. Clinicians treating
patients with NMOSD who later develop psychiatric symptoms, such as bizarre behavior, delusions, or
hallucinations, should consider testing for anti-NMDAR.
While there are no published cases of patients with NMDA encephalitis and MG, there have been reports of
concurrent MG and leucine-rich glioma-inactivated 1 (LGI1) protein antibody-associated encephalitis. This
disease process presents with characteristic faciobrachial seizures and the same psychiatric symptoms as
NMDA encephalitis [9]. The patient has not been tested for anti-LGI1 IgG at the time of writing. However,
the patient’s lack of seizures and negative limbic involvement on imaging make LGI1 encephalitis unlikely.
However, the association between these disorders should prompt anti-LGI1 IgG testing when patients with
MG present with symptoms of encephalitis.
In patients with concurrent MG and anti-AQP4 NMOSD, MG typically presented several years before
NMOSD, and the presentation of NMOSD did not correlate with cessation of MG immunosuppressive
therapy [4,8,10]. Patients typically tested positive for the anti-AQP4 antibody at the time of MG presentation
but did not show symptoms until years later [8]. Concurrent MG was not related to a worse prognosis in
patients with AQP4-NMOSD [10]. While thymic hyperplasia is a well-known source of anti-AchR, new
evidence suggests that the thymus could be a source of anti-AQP4 [7]. This could explain the increased
incidence of these disorders occurring together compared to chance. Although the patient’s imaging was
negative for a thymoma, CT is only 35% sensitive for thymic hyperplasia and 20% sensitive for a focal
thymic mass [11]. Therefore, the thymic origin of these disorders cannot be excluded. Individuals diagnosed
with MG should be tested for anti-AQP4 and counseled on the possibility of developing NMOSD in the
future.
The subsequent manifestations of these rare disorders are likely a consequence of coexisting autoimmunity.
NMDA encephalitis has been associated with concomitant demyelinating syndromes [3]. The mechanism
behind this phenomenon remains unclear. Malignancies and their associated paraneoplastic syndromes
often cause new-onset autoimmune disorders, including those seen in this patient. However, the patient’s
workup has been negative for malignancy thus far.
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Rituximab is a monoclonal antibody against the CD20 B-cell surface receptor. The binding of the antibody to
this receptor triggers B-cell death and has a powerful systematic immunosuppressive effect [12,13].
Conveniently, rituximab has been shown to be an efficacious treatment for all three disorders [14-16]. A
systematic review found that 30% of AchR+ patients saw decreased posttreatment antibody titers [14].
Response to rituximab is strong, with the majority of patients having some or all of their encephalitis
symptoms reversed posttreatment [16]. We believe the benefit of treating these three conditions with a
single drug will provide the best possible outcome for the patient with the least amount of side effects.

Conclusions
Over the course of two years, this patient developed the clinical manifestations of three rare neurological
autoimmune disorders at subsequent points in time. Not only did the symptoms of each disease overlap, but
also the patient had positive serology for all three conditions simultaneously. After failing first-line therapy
with glucocorticoids, she continues to respond well to rituximab. It is essential to address poor response
to first-line immunosuppressive therapies early on, as the continuation of these therapies may not be
effective in some cases. Additionally, central (NMOSD and NMDAR encephalitis) and peripheral (MG)
neurological syndromes can occur simultaneously and even present at distant points in time. Clinicians
need to be vigilant about the overlap of neurological syndromes affecting the central and peripheral nervous
systems to avoid delays in the diagnosis and treatment to prevent poor clinical outcomes.
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